Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSN814)

Drug Name
3,4,4',5-tetramethoxy-(Z)-stilbene Drug Info
Synonyms
CHEMBL47426; 134029-49-5; 1-Mtpe; NSC638499; Deoxycombretastatin A4; AC1NTUK5; ZINC5900; SCHEMBL3834841; (Z)-1,2,3-Trimethoxy-5-(2-(4-methoxyphenyl)ethenyl)benzene; cis-3,4,5,4'-tetramethoxystilbene; BDBM50006677; 10Z-3,4,4',5-tetramethoxystilbene; AKOS027382909; NSC-638499; 10Z-3,4,4'',5-tetramethoxystilbene; 3,4,4'',5-tetramethoxy-(Z)-stilbene; (Z) 3,4',5-TETRAMETHOXYSTILBENE; 5-(4-methoxystyryl)-1,2,3-trimethoxybenzene; (Z)-1,2,3-Trimethoxy-5-(4-methoxystyryl)benzene
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5388779
CAS Number
CAS 134029-49-5
TTD Drug ID
DMSN814

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Tubulin beta-2 chain (TUBB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vinblastine DM5TVS3 Advanced cancer 2A00-2F9Z Approved [2]
DOLASTATIN-10 DMDUV1S Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
3-bromo-4,4',5-trimethoxy-(Z)-stilbene DMPZ4M8 Discovery agent N.A. Investigative [1]
6-ile-ustiloxin DMQF8JG Discovery agent N.A. Investigative [3]
3,4',5-trimethoxy-(Z)-stilbene DMYHC3S Discovery agent N.A. Investigative [1]
Ustiloxin D DMA8JH7 Discovery agent N.A. Investigative [3]
Ustiloxin F DMT1LS0 Discovery agent N.A. Investigative [3]
2,3'-diamino-3,4,4',5-tetramethoxy-(Z)-stillbene DM2UWDR Discovery agent N.A. Investigative [1]
USTILOXIN A DMZP32O Discovery agent N.A. Investigative [3]
N-(4-(3-(pyridin-2-yl)acryloyl)phenyl)acetamide DMRH987 Discovery agent N.A. Investigative [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Tubulin beta (TUBB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vincristine DMINOX3 Acute lymphoblastic leukaemia 2A85 Approved [5]
Albendazole DMYZ57N Echinococcus granulosus infectious disease Approved [6]
Vindesine DMVR628 Acute lymphoblastic leukaemia 2A85 Approved [7]
Taxol DMUOT9V Breast cancer 2C60-2C65 Approved [8]
Mebendazole DMO14SG Ascariasis 1F62 Approved [6]
Plinabulin DMD7L48 Non-small-cell lung cancer 2C25.Y Phase 3 [9]
Batabulin DMHWE5R Solid tumour/cancer 2A00-2F9Z Phase 2/3 [10]
ABT-751 DMNG35S Solid tumour/cancer 2A00-2F9Z Phase 2 [11]
DOLASTATIN-10 DMDUV1S Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
BNC-105 DMJC8DR Mesothelioma 2C51.2 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Inhibitor [1]
Tubulin beta-2 chain (TUBB2) TTJ2PTI TBB2A_HUMAN Inhibitor [1]

References

1 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5.
2 Effect of the antitumor drug vinblastine on nuclear betaII-tubulin in cultured rat kidney mesangial cells. Invest New Drugs. 2003 Feb;21(1):15-20.
3 Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
4 Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J Med Chem. 2006 Sep 21;49(19):5664-70.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
7 Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36.
8 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
9 NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.
10 Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605.
11 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
12 The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60.